Biblio Discovery — Demo Discovery Service

33 results for "Samuel Singer"

Showing 1–20 · 1.67 seconds · RSS

  1. Journal Article

    MARGINALIZING TRANS MEDICAL EXPENSES: LINE-DRAWING EXERCISES IN TAX

    Samuel Singer

    The Windsor Yearbook of Access to Justice, Vol. 31 No. 2 · 2013 · French · DOAJ

    This article explores the treatment of trans medical expenses under American and Canadian tax laws. In both tax systems, medical expenses are deemed worthy of tax relief, while many cosmetic procedures are excluded. This article argues that tax administrators and the judiciary are influenced by…

  2. Journal Article

    The Case for Fixing the Unprincipled Residence Tax Exemption

    Allison Christians; Samuel Singer

    Osgoode Hall Law Journal, Vol. 62 No. 3 · 2026 · English · DOAJ Scopus

    When Canada overhauled its income tax to include capital gains in 1972, lawmakers suddenly had to decide how to deal with personal home sales. After heated debate, they opted to exclude the gains on an individual’s principal residence on the grounds that the core purpose of a home is to provide…

  3. Journal Article

    An Empirical Evaluation of Normalization Methods for MicroRNA Arrays in a Liposarcoma Study

    Li-Xuan Qin; Tom Tuschl; Samuel Singer

    Cancer Informatics, Vol. 2013 No. 12 · 2013 · English · DOAJ Scopus

    Background Methods for array normalization, such as median and quantile normalization, were developed for mRNA expression arrays. These methods assume few or symmetric differential expression of genes on the array. However, these assumptions are not necessarily appropriate for microRNA expression…

    Also available at: DOAJ

  4. Journal Article

    Exacerbation of paraneoplastic cerebellar degeneration by immune checkpoint inhibitor use in endometrial cancer

    Michael Danziger; Samuel Singer; Joan Tymon-Rosario

    Gynecologic Oncology Reports, Vol. 60 · 2025 · English · DOAJ Scopus

    Background: Immune checkpoint inhibitors (ICIs) have transformed the management of advanced and recurrent endometrial carcinoma (EC). ICI therapy can be associated with complex, multisystemic immune-related adverse events (irAEs), which present new challenges in gynecologic oncologic care…

  5. Journal Article Full text

    A differentiation-based phylogeny of cancer subtypes.

    Markus Riester; Camille Stephan-Otto Attolini; Robert J Downey et al.

    PLoS Computational Biology, Vol. 6 No. 5 · 2010 · English · DOAJ Scopus

    Histopathological classification of human tumors relies in part on the degree of differentiation of the tumor sample. To date, there is no objective systematic method to categorize tumor subtypes by maturation. In this paper, we introduce a novel computational algorithm to rank tumor subtypes…

    Also available at: PLOS

  6. Journal Article Full text

    Functional Copy-Number Alterations in Cancer

    Barry S. Taylor; Jordi Barretina; Nicholas D. Socci et al.

    PLoS ONE, Vol. 3 No. 9 · 2008 · English · PLOS Scopus

    Understanding the molecular basis of cancer requires characterization of its genetic defects. DNA microarray technologies can provide detailed raw data about chromosomal aberrations in tumor samples. Computational analysis is needed (1) to deduce from raw array data actual amplification or deletion…

    Also available at: DOAJ

  7. Journal Article

    The Oncolytic Activity of Myxoma Virus against Soft Tissue Sarcoma Is Mediated by the Overexpression of Ribonucleotide Reductase

    Yanghee Woo; Susanne G Warner; Rula Geha et al.

    Clinical Medicine Insights: Oncology, Vol. 15 · 2021 · English · DOAJ Scopus

    Background: Myxoma virus (MYXV) is an oncolytic poxvirus that lacks the gene for 1 of the subunits of ribonucleotide reductase (RR), a crucial DNA synthesis and repair enzyme. The overexpression of RR has been implicated in the invasiveness of several cancers, including soft tissue sarcomas (STS)…

  8. Journal Article

    ATRX is a regulator of therapy induced senescence in human cells

    Marta Kovatcheva; Will Liao; Mary E. Klein et al.

    Nature Communications, Vol. 8 No. 1 · 2017 · English · DOAJ Scopus

    Therapy induced senescence (TIS) is a growth suppressive program activated by cytostatic agents in some cancer cells. Here the authors show that the chromatin remodeling enzyme ATRX is a regulator of TIS and drives cells into this state via multiple mechanisms.

  9. Journal Article

    Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot

    Anna Lee; Jung J. Kang; Havah Bernstein et al.

    Cancer Medicine, Vol. 10 No. 13 · 2021 · English · DOAJ Scopus

    Abstract Patients with previously treated, recurrent or metastatic sarcomas who have progressed on multiples lines of systemic therapy may have limited options for local control. We evaluated outcomes of palliative proton therapy with the quad shot regimen to unresectable disease for patients with…

  10. Journal Article

    Targeting eIF4A-dependent translation in genetically complex sarcoma

    Young-Mi Kim; Prathibha Mohan; Urmila Sehrawat et al.

    JCI Insight, Vol. 11 No. 10 · 2026 · English · DOAJ Scopus

    Dedifferentiated liposarcoma (DDLS), myxofibrosarcoma (MFS), and undifferentiated pleomorphic sarcoma (UPS) are the most common types of genetically complex sarcoma. There is an urgent need to develop effective targeted therapy for these deadly sarcoma types. Despite their genetic complexity, these…

  11. Journal Article

    An interpretable AI model for recurrence prediction after surgery in gastrointestinal stromal tumour: an observational cohort studyResearch in context

    Dimitris Bertsimas; Georgios Antonios Margonis; Seehanah Tang et al.

    EClinicalMedicine, Vol. 64 · 2023 · English · DOAJ Scopus

    Summary: Background: There are several models that predict the risk of recurrence following resection of localised, primary gastrointestinal stromal tumour (GIST). However, assessment of calibration is not always feasible and when performed, calibration of current GIST models appears to be…

  12. Journal Article

    High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy

    Robert G Maki; Martina Bradic; Sandra P D’Angelo et al.

    Journal for ImmunoTherapy of Cancer, Vol. 13 No. 9 · 2025 · English · DOAJ Scopus

    Background Response to immune checkpoint inhibition (ICI) in sarcomas is overall low and heterogeneous. Understanding determinants of ICI outcomes may improve efficacy and patient selection. Thus, we investigated whether the expression of transposable elements (TEs), which are epigenetically…

  13. Journal Article

    A Prospective, Cohort Study of SITOIGANAP to Treat Glioblastoma When Given in Combination With Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Nivolumab or Granulocyte-Macrophage Colony-Stimulating Factor/Cyclophosphamide/Bevacizumab/Pembrolizumab in Patients Who Failed Prior Treatment With Surgical Resection, Radiation, and Temozolomide

    Daniela A. Bota; Thomas H. Taylor; Naomi Lomeli et al.

    Frontiers in Oncology, Vol. 12 · 2022 · English · DOAJ Scopus

    BackgroundGlioblastoma (GBM) is the most common primary, malignant brain tumor in adults and has a poor prognosis. The median progression-free survival (mPFS) of newly diagnosed GBM is approximately 6 months. The recurrence rate approaches 100%, and the case-fatality ratio approaches one. Half the…

  14. Journal Article

    Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

    Sandra P. D’Angelo; Allison L. Richards; Anthony P. Conley et al.

    Nature Communications, Vol. 13 No. 1 · 2022 · English · DOAJ Scopus

    The activity of PD-1 blockade in patients with sarcoma has been modest so far. Here, the authors report the results of a pilot clinical trial to assess the efficacy and safety of bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, in combination with the PD1 blockade…

  15. Journal Article Full text

    Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

    Benjamin Alexander Nacev; Francisco Sánchez-Vega; Shaleigh A. Smith et al.

    Nature Communications · 2022 · English · OpenAlex Scopus

    The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the identification of therapeutic targets, clinical research, and advancing patient care. Because there are > 100 sarcoma subtypes, in-depth genetic studies have focused on one or a few subtypes. Herein, we report a…